Research programme: targeted inflammation and autoimmune therapeutics - Affibody/Swedish Orphan Biovitrum
Alternative Names: IL-1 Affibody; SOBI 005; SOBI 006; Z-FCLatest Information Update: 28 Mar 2023
At a glance
- Originator Affibody; Biovitrum
- Developer Affibody; Swedish Orphan Biovitrum
- Class Proteins
- Mechanism of Action Complement C5 inhibitors; Immunomodulators; Immunosuppressants; Interleukin 1 beta inhibitors; Interleukin 1 modulators; Th17 cell inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Autoimmune disorders; Inflammation
Most Recent Events
- 28 Mar 2023 Discontinued - Preclinical for Autoimmune disorders in Sweden (Parenteral)
- 28 Mar 2023 Discontinued - Preclinical for Inflammation in Sweden (Parenteral)
- 28 Dec 2019 No recent reports of development identified for preclinical development in Autoimmune-disorders in Sweden (Parenteral)